与传统疗法相比，英夫利昔单抗和阿达木单抗抗TNF-A疗法治疗溃疡性结肠炎有效性的荟萃分析。

Anti-TNF-A therapy about infliximab and adalimamab for the effectiveness in ulcerative colitis compared with conventional therapy: a meta-analysis.

作者信息

Zhou Zheng, Dai Cong, Liu Wei-Xin

出版信息

Hepatogastroenterology. 2015 Mar-Apr;62(138):309-18.

Abstract

BACKGROUND/AIMS: TNF-α has an important role in the pathogenesis of ulcerative colitis (UC). It seems that anti-TNF-α therapy is beneficial in the treatment of UC. The aim was to assess the effectiveness of Infliximab and Adalimamab with UC compared with conventional therapy.

METHODOLOGY

The Pubmed and Embase databases were searched for studies investigating the efficacy of infliximab and adalimumab on UC.

RESULTS

Infliximab had a statistically significant effects in induction of clinical response (RR = 1.67; 95% CI 1.12 to 2.50) of UC compared with conventional therapy, but those had not a statistically significant effects in clinical remission (RR = 1.63; 95% CI 0.84 to 3.18) and reduction of colectomy rate (RR = 0.54; 95% CI 0.26 to 1.12) of UC. And adalimumab had a statistically significant effects in induction of clinical remission (RR = 1.82; 95% CI 1.24 to 2.67) and clinical response (RR = 1.36; 95% CI 1.13 to 1.64) of UC compared with conventional therapy.

CONCLUSION

Our meta-analyses suggested that Infliximab had a statistically significant effects in induction of clinical response of UC compared with conventional therapy and adalimumab had a statistically significant effects in induction of clinical remission and clinical response of UC compared with conventional therapy.

摘要

背景/目的：肿瘤坏死因子-α（TNF-α）在溃疡性结肠炎（UC）的发病机制中起重要作用。抗TNF-α治疗似乎对UC治疗有益。目的是评估英夫利昔单抗和阿达木单抗治疗UC相较于传统疗法的有效性。

方法

检索了PubMed和Embase数据库中研究英夫利昔单抗和阿达木单抗对UC疗效的研究。

结果

与传统疗法相比，英夫利昔单抗在诱导UC临床缓解（RR = 1.67；95%CI 1.12至2.50）方面有统计学显著效果，但在临床缓解（RR = 1.63；95%CI 0.84至3.18）和降低UC结肠切除术率（RR = 0.54；95%CI 0.26至1.12）方面无统计学显著效果。与传统疗法相比，阿达木单抗在诱导UC临床缓解（RR = 1.82；95%CI 1.24至2.67）和临床缓解（RR = 1.36；95%CI 1.13至1.64）方面有统计学显著效果。